A sustainable business model based on innovation and ... - Roche

More documents

Recommendations

Info

Personalised Healthcare Increasing demand by stakeholders Patients & Physicians Best treatment Regulators Better efficacy & safety profile Payers Better cost / benefit Industry More competitive 14
Scenarios for PHC Added Value Distribution Value captured by different stakeholders depending on IP and timing of diagnostic Breast Cancer Assay Rx Low IP for Diagnostic High Rx B-Raf inhibitor B-Raf mutant test Dx High High Dx Diagnostic after Drug Launch Payor Rx High Low Neutral High Payor Rx Diagnostic with Drug Launch Dx Medium Medium Dx K-Ras Test Payor High Neutral No IP for Diagnostic Payor Herceptin and Her2 test 15
Page 1 and 2: Roche A sustainable</strong
Page 3 and 4: Performance up-date Strategy Main t
Page 5 and 6: Performance up-date Our Strategy an
Page 7 and 8: Focus on our core business<
Page 9 and 10: Not to invest in the future means b
Page 11 and 12: Responsible management of R&D spend
Page 13: Main trends influencing the long-te
Page 17 and 18: Key drivers for long term developme
Page 19 and 20: Major growth opportunities outside
Page 21 and 22: First in class mechanisms establish
Page 23 and 24: Avastin: significant potential for
Page 25 and 26: ASCO 2009 Highlights Avastin NSABP
Page 27 and 28: Rheumatoid Arthritis: Not all patie
Page 29 and 30: Performance up-date Strategy Main t
Page 31 and 32: Profitability measures Operating ca
Page 33 and 34: Patent expiry 2008-2012 Roche short
Page 35 and 36: We Innovate Healthcare 35
Page 37: Top 10 Oncology Products Sales and

A sustainable business model based on innovation and ... - Roche

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?